INO - Earnings call transcript Q4 2021 | Inovio Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the Inovio Pharmaceuticals Fourth Quarter 2021 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Ben Matone, Senior Director of Investor Relations. ahead. go Please

Ben Matone

Good Inovio operator. thank for you Thank quarter afternoon, XXXX the fourth call. financial joining you, and results conference

Research on Vice Operating Senior of Dr. Twyman, Officer; Chief Dr. Vice are Laurent Humeau, Mr. President Financial today’s Officer; President Officer; President Broderick, and Dr. Dr. Kate me Mark Scientific Officer; Chief CEO; Development. Chief Peter and Dr. Joseph Shea, Clinical Jackie Commercial of Development; Chief and Senior Kies, Joining Kim, call Jeffrey Skolnik,

For year today’s medicines review DNA our will as our corporate the fourth on and for our call, we XX, platform. well financial quarter ended as update across information and XXXX an full provide efforts December

enrollment and milestones infectious and our other We programs. HPV-associated across dosing COVID-XX address will status as of achieved disease, the Inovio’s well efforts, as

Following conduct prepared reserved research analysts. question-and-answer for equity segment remarks, will a we

call call the concluded. available And factors to that Dr. to a statements data by press refer President call shortly actual time and with along performance documents Kim. develop This I website which cause file the the will webcast we of and important as Company. being These as expectations after During events will future the clinical the replay regulatory include SEC, ir.inovio.com. heading could turn making is verbally, relate and this business the regarding call, forward-looking DNA from of management made be to developments, and medicines, strategic well identify on today. are over the which integrated based statements platform readouts, these under differ the timing with on afternoon’s beliefs Factors and those capital Company of of Joseph as materially matters. you our the and will plans CEO, release. Inovio’s results now within to our future All made clinical from expressed is be this events We resources Inovio’s to Risk live statements time we

Dr. Joseph Kim

population appreciate join to The impact variants are and responses variants consistent the of in COVID-XX predominant may while countries, against XX% important ancestral an for the cell prevention may of have variant Since observed least of of INO-XXXX good that public of and prevention including challenge community. regulatory highlights endpoint certain has more vaccination transmissible COVID-XX of primary of of In the protection. death. as durability concern. INO-XXXX reaffirms while remain boosters, cell particularly, samples the Omicron plan to from of endpoint. The generate in this Ben, challenge X a responses expectation the market globally future both, T in responses past and concerns of In that the preservation and to Omicron are T to-date, taking Phase of everyone thought the and directly INO-XXXX impact afternoon. time is observation of disease the vaccine against improve a rates to from the threat Thank amend T fact response be unpredictability The primary amended of cell meant healthy clinical global ongoing seek We emergence infectious globe vaccines enduring can in first ability over across still trial ultimately cell nature below the boosters play proposed changed. COVID-XX, infections, XX%. to has today. number T to role Inovio for virus we they access all in against protection the and the disease vaccination continues central of months global you, and over vaccines dominance November, and Omicron There circulating few responses disease, available continued SARS-CoV-X, full COVID-XX and underscores Testament and prevent to variant Omicron in currently by variant to to symptomatic I ongoing current persistence The the individuals. not from to-date, could Omicron cross-reactive the our across to responses all maintenance that the in highly INNOVATE of the vaccinated of the for meant severe INO-XXXX’s to one clearly is the virus T vaccine believe all to meeting dose be cell the many generated of the be received significantly critical the variant done. work vaccinated has targeting the received this need approval growing protect to hospitalization highly Omicron. at us death, disease. across tested primary believe regard, VOCs severe severe and experts dose

who their reflect participants for the recommendation DSMB we trail. of In first potential Safety safety already impact to dosing form addition, issues dose. program enrollment Consent the Investigator were to Brochure those this and our a of participants The Omicron, continue and recommended received due INO-XXXX not Omicron factor the have the of Data Board Informed pause that that of new stated the emergence Monitoring under to in may update

first as participants in amend paused As as a endpoint, XXXX, data result our previously have be from primary to of half Innovate we the INNOVATE. the expected. Interim new therefore seek of to of trial’s plan efficacy DSMB will enrollment for available as approval well the recommendation, not

been waning than trial have doses vaccines are delivered to the to evaluating all widely a are candidates INO-XXXX by previously countries, boost pathway for vaccines. address also in to a -- globally, inactivated worldwide. heterologous non-inferiority administered for for conducted an inactivated a Viral vector additional booster vaccine booster in viral a the compared vector in more most This and boost ongoing of need approved evaluating trials our respect and trial, partner of clinical clinical meet complement which the and protection, ex-U.S. comparing feasibility that the as Currently trials. being approved will not China we’re heterologous addition, for Advaccine. boosters particularly vaccines regulatory COVID-XX In may considering some agencies their low types accounting with authorized half demand and to middle global clinical income COVID-XX

booster and disease the In for a boosting global a advantages studies addition transport, heterologous include favorable and re-administration, profile for features with of protection, construct of advantages to observed vaccine. heterologous match distribution confer desired advantages and boosting its suggest line thermostability independent for as early These scaling over approach, homologous immunity a DNA manufacturing. tolerability correspond INO-XXXX’s ease that data storage, key timely vaccine well from of mix may boost and T-cell for strategy design,

clinical to XXX-participant of We of heterologous the the tested the INO-XXXX Trial administered X/X Solidarity are sponsored the additional and the share also trial. is as and boost INO-XXXX And World where look the completed updates has as We which pleased homologous where as the Phase INO-XXXX its be control a as homologous boost boost The and are we primary quarter, to were by administered Vaccines, XXX-participant and evaluate Phase and designed ongoing inactivated progresses enrollment that vaccines as to trials a was in international WHO, with trials. selected vaccine. Advaccine WHO. immunogenicity heterologous last large as being tolerability Health safety, shared conducted sharing clinical forward Organization, trial, funded, randomized or Advaccine primary to X vaccine

turn who infectious infectious to effectively our I’ll vaccine diseases. our Kate select only proud well Senior R&D, DNA stage from truly the and for we platform INO-XXXX Vice while deep provide the support -- as INO pandemic believe the will disease for of variant, regarding COVID can community stage details INO-XXXX and Dr. co-program is progress it medicines most that experience programs. of COVID-XX other to Kate? our are Inovio combating further Broderick, With endemic DNA strength global Omicron program, as our the We We that, trial. as and lead this continued leveraging across shifts believe President over

Dr. Kate Broderick

you, everyone. full responses, Omicron variant the of of maintenance demonstrated CDX very immune including assessment responses vaccine-induced the important be Joseph, Inovio’s INO-XXXX in nice you vitro cell It’s all Thank of SARS-CoV-X to responses. against today. and T hello, of with cross-reactivity

levels seen as ancestral was of both variants. Omicron vaccine protection. with neutralizing important decreased and in However, the binding for central virus, the all We, responses believe COVID-XX with against along play against the T and of that be responses preservation of the a and cell against INO-XXXX many severe the role scientific durability vaccines to antibodies disease and date. significantly other of remain also to the the in they of consistent observation other protecting may Omicron cell death, maintenance showed developers, tested T concern community The an and variants

XXX Africa, There region estimated The at and priority. trial randomized is other vaccine Also the global we’re new as Inovio evaluate epidemic Accra, fever participants by from Jordan, MERS. finding Sponsored colleagues the programs, pathogens candidate full the ongoing we development Xb disease As to Joseph DNA Kenya. hard a potential, progress WHO by Phase the which in given our of healthy Institute for XXX clinical conducted funded is fever. have our illness Memorial pandemic for in funded is of, and of for our Lassa no advanced work illness noted, one our of making it we’ve trial infectious at for The partners. INO-XXXX, will trial for share that the Notably, Lassa safety, full completed this that endemic. of particularly of Inovio is and being against Phase CEPI, vaccine our includes in continued and trial double-blinded and X pleased adults for viral Research approved stage approximately XXX,XXX vaccine with completed health this Medical and immunogenicity Inovio vaccine currently the impacts fever, participants, Lassa trial where INO-XXXX in and enroll global viral to the in the Lebanon, first fully DNA I’m effective conducted tolerability, a total. by enrollment proud the vaccine, XXX Ghana. CEPI, enrollment West also of safe annually. people dose Noguchi also classifies trial placebo-controlled is candidate the sites our an

you. clinical example vaccine and participants XX safety, of Finally, placebo-controlled DNA Phase for and vaccinated as Xb candidate previously participants turn INO-XXXX our a with its of first November Thank DNA used enrollment it our trial completed INO-XXXX, tolerability dosed I’ll leveraging The to of a Ebola. be randomized Ervebo. Inovio’s will the in part first our in another assess can that, healthy booster immunogenicity we technology whether boosting medicines you, as participant its capacity, participant back evaluating of a and trial, Joseph. With healthy experience

Dr. Joseph Kim

Thank you, Kate.

remain needing other differentiating Development, to five-year all and important tolerability of to Our will efforts at health ultra-cold Jeffrey on platform, underscored be clinical our shelf of support year of and allows an the the to than storage room Clinical public environments at other cold frozen ever our measures SVP transport a programs. normal degrees update DNA diseases a Dr. in more or not Celsius our available. storage And and us have temperature refrigeration areas month be temperature widely and more our the now, where for XX for Jeffrey? at during ability may provide in medicines stable without Skolnik, than medicines, tropical attributes a life infectious DNA projected

Dr. Jeffrey Skolnik

very you Joseph. Thank much,

safety have also VGX-XXXX fourth As available disease we and cervical, that remained top-line programs, And tolerated follow-up week high-risk participants squamous global through trial We’ve HPV-associated of we XX-week to show completed clinical data the enrollment in or to our completed intraepithelial expect second VGX-XXXX of REVEALX, in REVEALX lesions, HSIL. Inovio efficacy quarter. which well XX. safety X our for relates it Phase the

remained Additionally, participants week treated endpoint clear and VGX-XXXX week HPV-XX primary the with of HPV-XX met at who XX. XX, and/or

outcome this those may serve HPV who liquid VGX-XXXX women cervical HSIL progress to are QIAGEN. guide treatment of validated, the And on of VGX-XXXX, HSIL. biopsy-based on in making generation favorable a clinical co-development and with diagnostic, to decision biomarker have diagnostic the sequencing specifically, more virus. to regression the is likely of use potential the technology may clearance for to identify a built This We next efforts of with have her cervical continue

year. this We information biomarker our expect later additional to have process on development

and life-threatening FDA characterized trial our to disease completed Phase due immunotherapy multicenter X/X our Phase to received Now, is a the in by expect the XXXX. by our from associated And is candidate these X safety, label incurable By HPV, update on RRP surgeries DNA X of is HPV can you second tract XX-associated clinical and/or which designation year-end, INO-XXXX to of open drug in RRP trial. XX lead tolerability, recurrent respiratory growth enrollment requires in HPV of in this portion we XX its a rare repeated airway tumors of participants caused assessing INO-XXXX, respiratory of and participants And preliminary papillomatosis. orphan XXXX. of immunogenicity with X/X HPV Inovio and July know, recurrence. RRP efficacy efficacy obstructions. to often as the from year. data half the treat

patients INO-XXXX, trial brain our This for opinion preconference INO-XXXX, Moving at the immuno-oncology combined months a the are GBM-XXX on MGMT have and in showed newly improve and with Reardon, that Inovio’s XX% coordinating presented acceptable of or glioblastoma unmethylated XX from November. XX for or the Phase GBF radiation DNA to data X leader newly was our out and key in survival trial, efforts. cohort. safety with methylated medicine XXXX, an and updated survival trial or next XX David for PI MGMT last and SITC diagnosed out promoter X Overall workshop Dr. for immunogenic INO- tumors our cemiplimab may chemotherapy our at cohort diagnosed XX XX% promoter in temozolomide GBF. profile,

to I’ll Joseph. we provide trial call updates participants to follow over in plan We the the continue in to future. and And back the now, turn additional

Dr. Joseph Kim

Thank for updates. clear you, Jeffrey,

Colombia’s financials, the government Social Colombia. This sharing, manufacturing building to and Inovio’s Inovio and discuss want producing creates related briefly year these local full with and -- a knowledge as Protection. for of signed can in of collaboration memorandum technology and of I quarterly results efforts our products understanding and platform, technologies. non-binding October our to Ministry moving and Health developing in The other Colombian capacity capabilities biopharmaceuticals developing potential by explore licensing, vaccines framework well Before which and that DNA and medicines include supports as across development MOU

will Now, summary. yearend quarter our and turn for Peter? Kies, to I the Peter our financial call CFO, fourth over

Peter Kies

afternoon, cash, investments $XXX.X Joseph, cash $XXX.X quarter term in fourth everyone. and Thanks, the We of with XX, to ended XXXX. million equivalents million and compared December good as short

on The manufacturing XXXX. costs ended and expenses operating and scale-up $XXX.X to million and was $XXX,XXX fully production December respectively, XXX in for XX, plasmid compared December million diluted expenses the shares Inovio million common in Total $XX.X for year million had and the XXXX. of XXXX million ended same same common As were shares quarter XXXX, in for operating to primarily to outstanding and year INO-XXXX. XX, was and and XXXX, million $XXX.X increase due related quarter basis. total periods to XXX.X device the million revenue $X.X compared outstanding XXXX, XX, $XXX December related $X.X periods million for a Total million in and to and $X.X

was million were and of a or was loss XXXX and higher ended other and dilutive million, December development XXXX. million per in outside quarter $XX.X trials ended acquisition related increase million the array share, share, $XXX.X R&D clinical and and same primarily $XX the versus million for year-over-year per dilutive, quarter and drug expenses to in related related the to $XXX.X in and to and $XX.X General in The XXXX CELLECTRA $X.XX dilutive, increase contractor Inovio’s and year-over-year compared manufacturing, related expenses and were to increase $X.XX million, ended million, research loss basic for and the the primarily expenses of $XX.X an variances. compensation, our expenses services per services, to to XX, the in higher and million $X.X the headcount for XXXX year XXXX. $XXX.X periods project, basic to INO-XXXX, and or G&A Our was share and employee net and increase respectively, for periods ended period installation to XXXX. and same December million million share higher and basic INO-XXXX, year other quarter XX, per basic $XX.X million compensation $XXX.X device engineering including equipment million $X.XX compared related or dilutive respectively, net administrative inventory expenses stock-based to related in expensed and for or for $X.XX compensation due manufacturing and The non-tax among expenses automation in XX, December employee variances. same employee and XPSP among $XX.X $XX.X year equipment

press statements that, can filed back release, the financial as as As form in Joseph. you, SEC. Company’s afternoon’s in full it with XX-K a I’ll reminder, with this you our find And to well the turn

Dr. Joseph Kim

Thank you, Peter.

take needs. diseases platform across DNA medicines quarter, our antibody to continued progress profile. open to advance responses, we tolerability, call that, efforts. to With and critical forward our express we cell We Inovio all questions. four their our global across these portfolio. appreciation continued committed our are encouraged in fulfilling let’s the funders, Without as trial full and we and for clinical progress efforts Before efforts closing, past to platform my team, strong Operator? as collective their In generate ability would sharing I able We entire of thankful our we medicines thermostability am enrollment functional to-date. to our the and our true advantages T well for across support for look in indications. we and due collaborators, the our advance not help HPV-associated cancer address This to want DNA diseases, questions, of four analyst be health combating potential contributions, as I are infectious the by completed to believe in trials unmet programs. vaccines their of partners proud of participants, and and

Operator

of Instructions] first will of Please [Operator ahead. come Our question Meacham Geoff from America. Bank go

Unidentified Analyst

Geoff taking Alex Hammond Thank our Hi. for you question. This on for is Meacham. [ph]

So, path on REVEALX forward for VGX-XXXX, in combo X And data with the patients submission the generated discussed have will trials? FDA? you QIAGEN to utilize for with you. a Phase bucket biomarker the Thank you

Dr. Joseph Kim

VGX-XXXX Alex Jeffrey Jeffrey? our Thank turn it Yes. over program Jeffrey I you, -- for lead, Dr. will question. to Skolnik.

Dr. Jeffrey Skolnik

Sure. And for question. Joseph. thanks Thanks, the

that are to or said VGX-XXXX. and advance that we development, most biomarker are are to Inovio identifying women very biomarker, signatures basically to that the be predict opportunity far. during validated vision continuing those so identify The will they by the respond signatures the those as likely identify VGX-XXXX. we biomarker continuing the to move able biomarker to And to progress prognosticate call, and those and That’s And QIAGEN essentially by women. we So, candidate forward. are our for potential have to the for ideally encouraged

both REVEALX for REVEALX know, designed the you the are studies biomarker in As and were that mind. potential with

considered And with biomarker question, that an us shown clearing we XX show for the always resolving and second to treated biomarker to To to can in secondary significant best VGX-XXXX be path population, women placebo. difference potentially has HSIL are important and your with the this this without those we’ve understand And biomarker. a engage part REVEALX between colleagues regulatory you program. and so, cervical answer forward the we as know, extremely looking of XX, statistically valuable the now

have our with and colleagues. best really forward to much to biomarker how utilize look that the to regulatory very we conversation understanding So,

Operator

go The next ahead. Singh Hartaj Oppenheimer. Please question of comes from

Hartaj Singh

disease already question, looking trial, before and ended XX%, right? reported for and against really trial talking Thank approval. steady vaccine progress On bivalent they Sanofi looked good. vaccines GSK And efficacy INNOVATE there. They’re Their of trial, for pretty Moderna’s the their the a endpoint hit. and your about good team, Omicron everybody. and Omicron. just Joseph you severe Hey,

you Phase you’re of protocol seems if on were vaccines vaccine development get in actual that disease severity So, current can or the ahead profile, the Is How a get it? quick proactive trying plus it that and what got X, to getting vaccine? profile profile the you a essentially successful product risk you’re product to to endpoint, market Omicron get and amendment? of I how thinking hospitalization Assuming the follow-up. approvals. do you thinking that benefit just are Would in endpoint, you about the

Dr. Joseph Kim

vaccine is. That’s is strain the vaccines some absolutely. against ones responses the Hartaj, testing, thrown Omicron. cell were and we Hi in T Kate as a great INO-XXXX which, CDX the that all What’s vaccine, targeted to Omicron that approved view the data including about antibody our by responses, Omicron from cells Yes. has maintained developers, of with curveball ancestral including in all Obviously, the described killer reduction earlier of have. T our myself fully and original

original the have believe even right, So, or whether that responses variants cell we’re targeting really that what’s variant, maintained. Beta, responses from to cell overall Gamma, Omicron that Delta, generated the Alpha, or full and and or leads T CDX next, next us even faith going our our be the persist to Omicron, stealth is we T INO-XXXX

we prevention So, emergency a are would once mind, in our with label vaccine and virus -- that’s our we And of Phase the full against all is high. once attributes X against position and the in the vaccine we data, step demonstrating have demonstrate that get of with disease COVID-XX taking of and as we SARS-CoV-X. that our knowing target severe that other this profile look success a mentioned that the proactive we for a benefits licensure INO-XXXX has earlier. get We and believe to strong probability

Hartaj Singh

in well in you’re up of approval. I matches and great. vaccines vitro data Yes, mean, the some Joe, against commercial pretty

Just planning for quick protocol on kind Omicron any the questions. just maybe Thanks amendments for variants, there? future to and the any they question also on updates there WHO of trial, doing are

Dr. Joseph Kim

Yes.

for speaks only WHO. As a process, WHO

speaking can you to is I being all impacted equally privy But, Omicron trials currently for vaccines them. tell not and undergoing. has what we’re So, developed

appropriately. they full and Trial know, you they as have to the Solidarity will full by the And we and. see trial confidence WHO most And as that the execute Vaccines be run sponsored is they So, control. have able

fall. So, had is they as the stated everything far, in so moving

Operator

Renza Next Capital Markets. of RBC question from Gregory comes

Unidentified Analyst

our to around to approval This change Greg. a meet the of you was and also, timeline taking primary your Thank some for the you questions. change could you. provide question primary the in regulatory size Thank you And Maybe if trial [ph] expect is Yinglu just for on seek expectations do steps on color wondering XXXX, the to for I first endpoint that? due endpoint? more

Dr. Joseph Kim

the steps through primary and is So, are amending to endpoint getting protocol their the trial getting amended regulators approved the overseeing in INNOVATE respective countries. and them the various modifying who

we expediently other So, regard. position, we expect committees. We well their ethics as I because that T a as local Omicron across case very variants we to think maintenance a of these occur of in possible strong in think, as have concern, against the have that next and as bodies and regulatory strong cell our

is of of death at time. the sample case change and on execution. such size sizing, that the time don’t into significantly trial we terms based tested. INNOVATE to our including severe territories all that expect is hospitalization, this we In INNOVATE evaluating that those But across the course, of various being fed real rates, is are And information

Unidentified Analyst

XXXX. question another maybe And on

learn Just Thank we trial. clarify you. were expect readout. And any more adjustments should of just timeline design the wondering REVEALX to for to if granularity there wanted trial I when on the

Dr. Joseph Kim

quarter our follow-up. a in expert, last I patient weeks about the Yes. enrolled as REVEALX in it I’m trial and Skolnik going will question fourth that. fully But to the there’s in follow-up of we let Dr. XXX address if XX take participants

protocol. one data of and have immunogenicity instead And fourth no, month projection is and efficacy XXXX. So, REVEALX preliminary REVEALX of had safety would follow-up, safety year. we follow-up in haven’t It’s to quarter identical we any changes is to our except one the the

Operator

of ahead. Willey The next from question Stephen go Please comes Stifel.

Stephen Willey

say able the to were the how Are patients many of time INNOVATE at into you enrolled pause?

Dr. Joseph Kim

period. dosed. Yes. -- up new to been to number -- enrollment But No, date pause the the volunteers information. provide that’s policy have were we to just paused. they during the And we of and receive continue it’s who dose follow significant our second will we It’s not have

Stephen Willey

across incidence X Okay. Novavax And X question, the it’s, like vaccine that to you severe I of the then, to studies X right? So, and whether participants, disease Pfizer, X,XXX seen to follow-up just is look anywhere Moderna, is X,XXX Phase or guess, maybe on when trials, between last the X,XXX across participants. those rate

patients disease, in there I presumably that of you guess, severe X,XXX in chance the see single digit severe meaningfully do contemplate that I how a low statistical study? of size guess, lower setting you is not I number a And from X,XXX rates Omicron context changing of the when mean, of is generating a about events? perspective, the you power a think study, they So, how to where

Dr. Joseph Kim

Yes. a great question. That’s

We’re still XX% our power. size powering to sample

out. severe XX% Omicron incidences your getting endpoint, a is it being XX% that’s driver while reduced true believe, point major I disease will us to about been of we fair think of higher So, so of that one. the equalize has severity But, I the infection by Delta, believe the the a incidences infections of

I to think trial. our to achieve sample XX,XXX, we those rates objectives that we and mentioned, are projected continually be expect be across disease size we severe we and have I had monitoring initially But going as we territories. with And will We be able those X,XXX feel evaluated to the INNOVATE impacts, fairly around forward. our good as we these should

Stephen Willey

with with should we about first year? the the being of know trends if paused. conjunction that the And Okay. But, Peter. maybe some uncertainty think I INNOVATE there’s How during spend pace pause? fairly anticipate in of a obviously the step where then, for just just we kind down half question in there’s significant And should here R&D OpEx a of any…

Peter Kies

No.

on with lot in of going areas ongoing a have We efforts this.

the see quarters, So, I think in million fairly the running remain about, $XX to burn other range you’re per quarter. it consistent with going

Operator

comes question of from next Song ahead. Please The go Roger Jefferies.

Roger Song

taking our for you question. Thank Great.

question the that’s one booster. So, related to

comment Phase will booster you next for timing also, homologous? for what be the for the X/X the the what those just step So, or will And Joseph, heterologous look like the can regimen? data booster,

Dr. Joseph Kim

Yes.

They enrolled. The and Roger. you, of to that’s the quarter thank year. homologous fully expect data heterologous in this vaccine So, trials, have second the boost

China, being it’s by course executed partner our run Advaccine. in So, of and

So, we sometime quarter. that data next trial expect the from in the

a boost, viral of trial, with heterologous ability terms of can deeply vector execution COVID the in In prolifically feasibility vaccine boost utilized U.S. and two heterologous most additional investigating compare other we’re and inactivated primary for vaccines. where the again we outside

the go, in stage. and we’re through this we feasibility a think But, this XXXX. execute if planning is can all So, we

Roger Song

Got any very pan-coronavirus know And just own you. it. kind Thank your That’s have also, XXXX, we vaccine the of regarding progress? helpful. you update

Dr. Joseph Kim

Broderick, to address turn Kate? I’ll Dr. that. to Maybe absolutely. Yes,

Dr. Kate Broderick

question. the vaccines we Thanks in. that’s much. are very our Yes. the very is pan-coronavirus excited pan-COVID field this whole has pre-clinically to and very able that develop about INO-XXXX striking COVID discussion generate in what interested board, across our continue shown But including are what’s Really, we’re certainly vaccines moment very at particularly INO-XXXX the It’s that something We the thus about pan-COVID cell pertinent to is far. great it. vaccine really and T response

Omicron, wrench responses. all still works face maintaining was important So, in even of the we’re in those the T-cell the that

So, our very excited able are vaccines and we’re what to about very encouraged generate.

Roger Song

Got it.

questions. taking our Okay. Thanks for

Dr. Joseph Kim

Yes. Thank you.

Operator

go comes of ahead. question Yi from next Please Wainwright. The H.C. Chen

Yi Chen

you think first for is, VGX-XXXX, biomarker? fully the you additional taking to an you developed question you clinical biomarker possible once the that Thank question. need trial the have my do for using it My is will conduct

Dr. Joseph Kim

turn question. Skolnik with VGX-XXXX. Hi, Again, a Dr. I’ll to over good very Yi. question That’s this for

Dr. Jeffrey Skolnik

both, looking biomarker. and this REVEALX REVEALX that predictive at mentioned As potentially anticipated before, always we remember examining,

ultimately, always has biomarker ask it and REVEALX already the those our a both opportunities question attention protocols. been to truth in are in REVEALX. And So,

our studies of them. continue we’re have, respect these And always clearly, have regulatory then, opportunities ultimately, all to colleagues. we’ll But with answer we So with biomarker. to forward, been our moving and two to going question, that again, to intention this certainly to that explore potentially your conversation the with to it’s utilize examine

Yi Chen

question respect year? what next this the catalysts this GBM, in the is, next for expected with to are the And is and step program XXXX what

Dr. Joseph Kim

standard-of-care share you this the Well, hard-to-treat very following which we’re continually our Skolnik these cancer Jeffrey is compared encouraging data, to patients. types in with in OSXX very GBM.

with our steps evaluating we’re them, our follow Regeneron. to continue we’ll next collaborator So,

following for of into path the participants as these program. this well as forward will the survival, us surviving overall think give I additional So, insights

Yi Chen

results when to vaccine? do to And my trial X from question you XXXX of expect Phase is, last report MERS

Dr. Joseph Kim

Yes.

going over So, Kate? to turn to Kate. that I’m

Dr. Kate Broderick

minute Could the sorry. went for I’m bad a part. question so repeat me? line for you The

Yi Chen

When Phase MERS report of results vaccine? do the X you the trial to from expect

Dr. Kate Broderick

Yes. Great question.

we’re still we’re So, the moment, enrolling, and at now. currently through about halfway

So, by this probably QX of year.

Operator

the concludes back This for turn remarks. over any Joseph session. Kim would to conference closing our like I question-and-answer to

Dr. Joseph Kim

year much you and quarter to XXXX Thank our very conference listening fourth full for call.

look ahead them sharing forward much. in all these very ‘XX coming Thank exciting an we us have We with in of to months. and of programs, year you the with you

Operator

The attending conference concluded. now is disconnect. Thank you presentation. may now you today’s for And

Inovio Pharmaceuticals (INO) 2 Mar 222021 Q4 Earnings call transcript